NASDAQ · CTMX
Healthcare · Biotechnology
$2.18
Up+$0.04 (+1.61%)
Updated Nov 4, 2026, 3:45 PM
SID Score
4.5/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · CTMX
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 3, 2026
CTMX closed at $2.18 after 21 trading sessions, down 14.84% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 3, 2026 | $2.24 | $2.32 | $2.155 | $2.18 | 3.42M |
| Nov 2, 2026 | $2.36 | $2.39 | $2.14 | $2.23 | 9.47M |
| Oct 30, 2026 | $2.28 | $2.36 | $2.21 | $2.34 | 4.94M |
| Oct 29, 2026 | $2.38 | $2.42 | $2.25 | $2.29 | 4.63M |
| Oct 28, 2026 | $2.28 | $2.385 | $2.25 | $2.36 | 4.08M |
| Oct 27, 2026 | $2.21 | $2.36 | $2.16 | $2.31 | 3.73M |
| Oct 26, 2026 | $2.31 | $2.33 | $2.18 | $2.225 | 5.22M |
| Oct 23, 2026 | $2.41 | $2.42 | $2.305 | $2.32 | 4.37M |
| Oct 22, 2026 | $2.38 | $2.47 | $2.37 | $2.44 | 2.44M |
| Oct 21, 2026 | $2.525 | $2.61 | $2.39 | $2.40 | 3.11M |
| Oct 20, 2026 | $2.36 | $2.55 | $2.34 | $2.51 | 4.1M |
| Oct 19, 2026 | $2.31 | $2.35 | $2.24 | $2.34 | 2.05M |
| Oct 16, 2026 | $2.40 | $2.45 | $2.26 | $2.28 | 3.18M |
| Oct 15, 2026 | $2.26 | $2.435 | $2.25 | $2.41 | 2.99M |
| Oct 14, 2026 | $2.30 | $2.345 | $2.20 | $2.23 | 3.35M |
| Oct 13, 2026 | $2.45 | $2.45 | $2.32 | $2.325 | 5.22M |
| Oct 12, 2026 | $2.56 | $2.575 | $2.41 | $2.42 | 4M |
| Oct 9, 2026 | $2.46 | $2.58 | $2.44 | $2.57 | 3.04M |
| Oct 8, 2026 | $2.51 | $2.545 | $2.43 | $2.47 | 4.5M |
| Oct 7, 2026 | $2.53 | $2.65 | $2.52 | $2.55 | 2.34M |
| Oct 6, 2026 | $2.61 | $2.63 | $2.505 | $2.56 | 1.96M |
The latest Smart Investors Daily articles mentioning CTMX.
Company
Market Activity
Research & News
CTMX research
Company profile and research snapshot.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 13, 2026 | JP Morgan | Overweight | — |
| Aug 10, 2026 | Guggenheim | Buy | — |
| May 11, 2026 | HC Wainwright & Co. | Buy | — |
| Mar 23, 2026 | Piper Sandler | Overweight | — |
| Mar 19, 2026 | Barclays | Overweight | — |
No generated briefing is available yet.
SeekingAlpha · Sep 14, 2026
CytomX Therapeutics, Inc. (CTMX) Morgan Stanley 24th Annual Global Healthcare Conference September 14, 2026 1:50 PM EDTCompany ParticipantsChris Ogden -...
SeekingAlpha · Sep 10, 2026
2026-09-10. The following slide deck was published by CytomX Therapeutics, Inc.
Yahoo · Sep 1, 2026
SOUTH SAN FRANCISCO, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that management will participate in the following investor conferences in September. Wells Fargo 21st Annual Healthcare ConferenceDate: Tuesday, September 8, 2026 Fireside Chat: 2:15 p.m. ETLocation: Boston, MA 2026 Cantor Global Healthcare ConferenceDate: Wednesday, September 9, 2026Fireside Chat: 10:20 a.m.
Yahoo · Aug 27, 2026
- Fast Track Designation follows encouraging Phase 1 data that were previously reported for R/R mCRC - - Potential Varseta-M monotherapy registrational study in R/R mCRC planned for initiation in 1H 2027 - SOUTH SAN FRANCISCO, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to Varseta-M fo
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning CTMX.
